MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis

Summary

The purpose of this study is to evaluate biosimilarity between test product MabionCD20® and the reference product - MabThera® (rituximab) and to demonstrate comparative safety and tolerability of a single course of treatment of MabionCD20® and MabThera® in patients with moderate to severe active rheumatoid arthritis.

Timeline

Start

2013-05

Primary completion

2017-05

Completion

2017-10

Drugs

Indications